Jessica Tassan
Stock Analyst at Piper Sandler
(0.85)
# 3,975
Out of 5,180 analysts
86
Total ratings
23.29%
Success rate
-16.84%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jessica Tassan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CI The Cigna Group | Reiterates: Overweight | $374 → $370 | $258.08 | +43.37% | 5 | Mar 3, 2026 | |
| TDOC Teladoc Health | Reiterates: Overweight | $12 → $9 | $5.14 | +75.10% | 7 | Feb 26, 2026 | |
| DOCS Doximity | Maintains: Overweight | $40 → $42 | $23.73 | +76.99% | 6 | Feb 20, 2026 | |
| OMCL Omnicell | Reiterates: Overweight | $63 → $49 | $32.35 | +51.47% | 5 | Feb 6, 2026 | |
| HNGE Hinge Health | Maintains: Overweight | $71 → $60 | $36.77 | +63.18% | 3 | Jan 9, 2026 | |
| ALHC Alignment Healthcare | Maintains: Overweight | $20 → $30 | $16.85 | +78.04% | 6 | Jan 6, 2026 | |
| CVS CVS Health | Reiterates: Overweight | $99 → $101 | $70.14 | +44.00% | 6 | Dec 10, 2025 | |
| OSCR Oscar Health | Upgrades: Overweight | $13 → $25 | $10.85 | +130.41% | 7 | Nov 26, 2025 | |
| UNH UnitedHealth Group | Maintains: Overweight | $423 → $417 | $261.79 | +59.29% | 9 | Oct 29, 2025 | |
| PHR Phreesia | Maintains: Overweight | $33 → $34 | $11.41 | +197.98% | 6 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $2.17 | +729.49% | 4 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $1.18 | +238.98% | 12 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $86 | $15.81 | +443.96% | 3 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $288 → $272 | $166.00 | +63.86% | 4 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 → $8 | $5.17 | +54.74% | 3 | May 23, 2025 |
The Cigna Group
Mar 3, 2026
Reiterates: Overweight
Price Target: $374 → $370
Current: $258.08
Upside: +43.37%
Teladoc Health
Feb 26, 2026
Reiterates: Overweight
Price Target: $12 → $9
Current: $5.14
Upside: +75.10%
Doximity
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $23.73
Upside: +76.99%
Omnicell
Feb 6, 2026
Reiterates: Overweight
Price Target: $63 → $49
Current: $32.35
Upside: +51.47%
Hinge Health
Jan 9, 2026
Maintains: Overweight
Price Target: $71 → $60
Current: $36.77
Upside: +63.18%
Alignment Healthcare
Jan 6, 2026
Maintains: Overweight
Price Target: $20 → $30
Current: $16.85
Upside: +78.04%
CVS Health
Dec 10, 2025
Reiterates: Overweight
Price Target: $99 → $101
Current: $70.14
Upside: +44.00%
Oscar Health
Nov 26, 2025
Upgrades: Overweight
Price Target: $13 → $25
Current: $10.85
Upside: +130.41%
UnitedHealth Group
Oct 29, 2025
Maintains: Overweight
Price Target: $423 → $417
Current: $261.79
Upside: +59.29%
Phreesia
Sep 5, 2025
Maintains: Overweight
Price Target: $33 → $34
Current: $11.41
Upside: +197.98%
Aug 28, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $2.17
Upside: +729.49%
Aug 27, 2025
Downgrades: Neutral
Price Target: $8 → $4
Current: $1.18
Upside: +238.98%
Aug 15, 2025
Maintains: Overweight
Price Target: $44 → $86
Current: $15.81
Upside: +443.96%
Jul 31, 2025
Maintains: Neutral
Price Target: $288 → $272
Current: $166.00
Upside: +63.86%
May 23, 2025
Reiterates: Neutral
Price Target: $10 → $8
Current: $5.17
Upside: +54.74%